AI, SAMD, Application
The company was founded in October 2019 by Dr. Takaki, a Japanese intensivist with more than 20-year experience in critical care medicine, from his strong desire of wanting to decrease preventable death and sudden changes in patient conditions while in the ICU. CROSS SYNC’s vision is to provide ICU-level medical treatment anywhere. The mission is to help and assist medical professionals utilizing the power of technology so that they can provide high-quality medical care even in an environment where there is a shortage of specialist physicians, and to ensure the best patient outcomes.As a Yokohama University certified startup, CROSS SYNC develops a variety of AI clinical assistant tools in collaboration with affiliated hospitals, the school of medicine, and the department of health data science. By delivering our AI-based platform to acute care settings all over the world, we aim to create a world without avoidable deaths and preventable acute changes for in-patients.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Mar 8, 2021 | Seed | ¥150M | 4 | — | — | Detail |
Date
Company Name
|
Round | Money Raised | Industry | Lead Investor |
---|---|---|---|---|
Sep 19, 2019
Square Yards
|
Series Unknown | $20M | Market Research | — |
Jan 23, 2014
RedMart
|
Series Unknown | $5.40M | E-Commerce | Yes |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Development Bank of Japan | — | Seed |
Findex | — | Seed |
Konica Minolta | — | Seed |
Toyota Tsusho | — | Seed |